Cancer therapeutics company double win with $25M and board member

An mRNA-technology company developing cancer therapeutics designed to improve patients’ survival rate and quality of life — this week announced the completion of a $25 million Series A financing.

Kernal Biologics, Inc. (Kernal Bio)  confirmed that the funding was  led by…

Source: www.labiotech.euRead more